FMS - DaVita stock dips as peer Fresenius outlook weighed down by labor cost inflation
- DaVita ( NYSE: DVA ) stock fell ~6% premarket July 28 after peer dialysis services provider Fresenius Medical Care ( FMS ) said it was cutting its outlook for FY22 due to increased headwinds from U.S. labor market and global inflation and also withdrawing its 2025 targets.
- Fresenius shares fell ~13% premarket following the announcement.
- YTD, DaVita stock has fallen ~24% while Fresenius has shed ~31%. See chart here .
- The SA Quant Rating and also the average Wall Street Analysts' Rating on DaVita is Hold .
- Meanwhile, the SA Quant Rating on Fresenius is Hold , which is in contrast to average Wall Street Analysts' Rating of Buy .
- DVA -5.66% to $82 premarket July 28
For further details see:
DaVita stock dips as peer Fresenius outlook weighed down by labor cost, inflation